REPLIMUNE GROUP, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REPLIMUNE GROUP, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2019-03-31 was $79.27M.
- REPLIMUNE GROUP, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-12-31 was -$79.27M.
- REPLIMUNE GROUP, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-09-30 was $86.36M.
- REPLIMUNE GROUP, INC. stock issued during period, value, conversion of convertible securities for fiscal 2019 was $86.36M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2019-03-31 | $79.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $86.36M 10-K · filed 2020-06-03 |
| 2018-12-31 | -$79.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13 | |
| 2018-09-30 | $86.36M 10-Q · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |